PI3K/Akt/mTOR路径:在IR/MASH相关的肝细胞癌中免疫代谢编排
Jian Zhao1, Yuehua Zhang2, Zhigong Wei3
1Thoracic Oncology Ward, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, P.R. China.
胰岛素耐药性和与代谢功能障碍相关的胆固醇肝炎通过重新编程PI3K/Akt/mTOR途径来驱动肝癌. 这种重新连接创造了一个免疫抑制的瘤微环境,为肝细胞癌提供了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 代谢疾病 代谢疾病
- 免疫学 免疫学 免疫学
背景情况:
- 胰岛素耐药性 (IR) 和与代谢功能障碍相关的型肝炎 (MASH) 是肝细胞癌 (HCC) 的重要危险因素.
- 在HCC中,IR和MASH诱导免疫抑制瘤微环境 (TME) 的机制尚未完全理解.
- 了解这些机制对于开发有效治疗这种侵袭性癌症亚型至关重要.
研究的目的:
- 审查和阐明PI3K/Akt/mTOR信号通路如何在IR/MASH相关的HCC中整合病理信号.
- 突出该途径在TME内的瘤代谢重编程和免疫细胞调节中的作用.
- 为在IR/MASH-HCC的临床干预中针对这种途径提供理论基础.
主要方法:
- 文献综述侧重于PI3K/Akt/mTOR途径在IR,MASH和HCC的背景下.
- 分析IR/MASH条件如何"打印"或重新连接PI3K/Akt/mTOR路径.
- 检查该途径在代谢重编程,免疫逃避 (例如PD-L1,EMT) 和免疫细胞功能中的作用.
主要成果:
- PI3K/Akt/mTOR通路作为HCC中IR/MASH驱动的病理信号的中心整合器.
- "印记"PI3K/Akt/mTOR信号驱动瘤代谢重编程,并重塑TME的免疫格局.
- IR/MASH协同增强途径介导的免疫逃避,包括PD-L1上调和上皮层-介质细胞过渡 (EMT).
结论:
- PI3K/Akt/mTOR通路是IR/MASH-HCC中侵袭性免疫代谢表型的关键"处理单元".
- 这一框架阐明了IR/MASH-HCC及其免疫抑制TME的独特生物学.
- 针对PI3K/Akt/mTOR途径,可能与组合策略和生物标志物相结合,为新的临床干预提供了一个有希望的途径.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Abnormal Proliferation
